Scribe Therapeutics is a biotech company that develops and engineers new therapeutics based on CRISPR molecules.
Scribe Therapeutics is a biotech company that develops and engineers new therapeutics based on CRISPR. The company’s first technology, called X-Editing (XE) molecules, are highly engineered CRISPR enzymes that provide combined aspects of greater efficacy, specificity, and deliverability than currently available CRISPR genome editing technology. It also a long-term, engineering approach that can help establish CRISPR-based therapies as a new standard of clinical care and expand access to groundbreaking treatments that will impact millions of lives.Scribe Therapeutics is overcoming the limitations of current genome editing technologies by developing custom-engineered enzymes and delivery modalities as part of a proprietary, evergreen platform for CRISPR-based genetic medicine. The company built for exceptional specificity within the genome – enabling therapeutic precision and allele-specific targeting.Scribe Therapeutics was founded in 2018 and is headquartered in Alameda, CA, USA.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Mar 31, 2021 | Series B | $100M | 9 | Avoro Capital Advisors Avoro Ventures | — | Detail |
Jan 1, 2018 | Series A | $20M | 1 | Andreessen Horowitz | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Avoro Capital Advisors | Yes | Series B |
Avoro Ventures | Yes | Series B |
Andreessen Horowitz | — | Series B |
Menlo Ventures | — | Series B |
OrbiMed | — | Series B |
Perceptive Advisors | — | Series B |
RA Capital Management | — | Series B |
T. Rowe Price | — | Series B |
Wellington Management | — | Series B |